Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Fast, facile, hypersensitive assays for ribonucleolytic activity

C Park¹, B R Kelemen, T A Klink

¹Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.

Methods in Enzymology

|October 5, 2001

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Retrospective Review of Real-World Patterns of Biologic Use in Dermatology Across Metropolitan, Regional and Rural Settings.

The Australasian journal of dermatology·2026

Same author

Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21).

ESMO open·2025

Same author

Implementation of an automated, real-time mortality prediction tool in trauma patients: Can it do more than just predict mortality?

Injury·2025

Same author

Percutaneous core needle biopsy of 566 peripheral lung lesions: analysis of factors associated with biopsy failure and postprocedural pneumothorax.

Clinical radiology·2025

Same author

Corrigendum to "An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations": [ESMO Open 10 (2025) 104106].

ESMO open·2025

Same author

An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations.

ESMO open·2025